Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Buy” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company.

Several brokerages recently issued reports on BAYRY. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd.

Bayer Aktiengesellschaft Trading Down 2.7%

Shares of BAYRY opened at $13.43 on Thursday. The firm has a market capitalization of $52.78 billion, a price-to-earnings ratio of -20.98, a PEG ratio of 4.43 and a beta of 0.55. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70. Bayer Aktiengesellschaft has a 1-year low of $7.19 and a 1-year high of $15.23. The company has a 50-day moving average of $11.88 and a 200 day moving average of $11.92.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. The business had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, research analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.